Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT06579872
Recruiting Observational

Association Between Cardiopulmonary Function and Plantar Pressure in Patients With Chronic Obstructive Pulmonary Disease

NCT06579872 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Fu Jen Catholic University
Phase
Observational
Started
2024-12-12
Last updated
2026-02-27

Condition(s) studied

Chronic Obstructive Pulmonary Disease

Investigational drug(s) / intervention(s)

plantar pressure

plantar pressure: foot pressure analysis, cardiopulmonary function, and mobility in patients with chronic respiratory diseases

Study summary

It aims to understand the differences in everyday mobility and activity capabilities among patients with varying disease progression and severity, to serve as reference indicators for evaluating the effectiveness of pulmonary rehabilitation exercise training.

Eligibility

Sex
ALL
Min age
45 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age between 45 and 65 years * Patients with chronic respiratory diseases requiring pulmonary rehabilitation * Signed informed consent form Exclusion Criteria: * Current tracheostomy * Home use of oxygen therapy or ventilators * Diagnosed with severe left heart failure (NYHA III-IV) * Patients diagnosed with neuromuscular diseases * Had an acute exacerbation of COPD in the past three months * Unable to perform cardiopulmonary exercise testing

Primary outcome measure(s)

  • plantar pressure — 20 minutes
    The correlation between foot pressure indices and functional tests

Trial sites (1)

FacilityCityRegionStatus
Fu Jen Catholic University Hospital, Fu Jen Catholic University New Taipei City Taiwan Recruiting

More Fu Jen Catholic University trials in Taiwan

Multimodal Deep Learning Model for Predicting the Apnea-Hypopnea Index in Obstructive Sleep Recruiting
Utilizing 3D Printed Personalized Aortic Lesion Models in Preoperative Assessment Recruiting
AI-Powered Virtual Human Simulation in Students Starting soon
Effects of Eccentric Exercise Training in Patients With COPD Recruiting
Effects of Mobilization Using a Powered Lower-limb Exoskeleton With Prolonged Mechanical Ventilation Recruiting

Other trials for the same condition

Effects of TPB-Based Cadence Exercise and Breathing Training on Physiological Parameters and Quality of Life in Patients With COPD Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype Recruiting
Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells Recruiting
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo Recruiting
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06579872 on ClinicalTrials.gov ↗ ← All trials in Taiwan